Allspring Global Investments
AKBA icon

Allspring Global Investments’s Akebia Therapeutics AKBA Stock Holding History

Allspring Global Investments’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-242,866
Closed -$76K – 2903
2022
Q3 		$76K Buy
242,866
+73,924
+44% +$29K ﹤0.01% 2182
2022
Q2 		$59K Sell
168,942
-180,710
-52% -$75.8K ﹤0.01% 2206
2022
Q1 		$251K Buy
349,652
+41,740
+14% +$89.3K ﹤0.01% 2496
2021
Q4 		$695K Buy
+307,912
New +$840K ﹤0.01% 2147

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $715M AUM 19.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Allspring Global Investments's AKBA Position: Q4 2022 in Review

Allspring Global Investments sold out of Akebia Therapeutics (AKBA) in Q4 2022, closing a stake of 242,866 shares — an estimated $76K sold.

Allspring Global Investments first reported a position in AKBA in Q4 2021 and held it in 4 quarters. The position peaked at $695K in Q4 2021. 75 funds tracked by Wall St. Rank hold AKBA as of Q4 2022.

  • Allspring Global Investments reported no remaining Akebia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Allspring Global Investments sold 242,866 Akebia Therapeutics shares in Q4 2022, an estimated $76K.
  • Allspring Global Investments first reported a position in Akebia Therapeutics in Q4 2021 and held it in 4 quarters.
  • Allspring Global Investments's Akebia Therapeutics position peaked at $695K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2022.

Based on Allspring Global Investments's 13F filing for Q4 2022, filed 23 Jan 2023.